A database of FDA approved therapeutic peptides and proteins
ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1055 | Th1009 | Alteplase | SYQVICRDEKTQMIYQQHQS Full view | 255 | Ib | Hematological,Metabolic | Activase | Genentech Inc | Sterile, white to off-white, lyophilized powder | Intravenous | Thrombolytic Agents | Plasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1 |
1067 | Th1012 | Reteplase | SYQGNSDCYFGNGSAYRGTH Full view | 255 | Ib | Hematological,Metabolic | Retavase | Centocor | Sterile, white, lyophilized powder | Intravenous Injection | Fibrinolytic Agents, Thrombolytic agents | Plasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1 |
1117 | Th1016 | Pegfilgrastim | MTPLGPASSLPQSFLLKCLE Full view | 175 | Ib | Immunological | Neulasta | Amgen Inc. | Solution | Subcutaneous injection | Immunosuppressive Agents, Anti-neutropenic agents | Granulocyte colony-stimulating factor receptor,Neutrophil elastase |
1148 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Advate | N.A. | Powder form | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
1149 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Alphanate | N.A. | Lyophilized powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
1150 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Bioclate | Baxter Healthcare Corporation, Hyland Division and Genetics Institute, Inc. | Sterile, nonpyrogenic, off-white to faint yellow, lyophilized powder | Intravenous infusion | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
1151 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Helixate FS | N.A. | Sterile, stable, purified, nonpyrogenic, dried concentrate | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
1152 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Hemofil M | N.A. | Dry concentrate | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
1153 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Hyate:C | N.A. | Powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
1154 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Koate-HP | N.A. | Powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
1155 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Kogenate FS | N.A. | Powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
1156 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Monarc-M | N.A. | Powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
1157 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Monoclate-P | N.A. | Lyophilized powder for solution | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
1158 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | ReFacto | N.A. | Lyophilized powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
1159 | Th1022 | Antihemophilic Factor | ATRRYYLGAVELSWDYMQSD Full view | 255 | Ia | Hematological,Metabolic | Xyntha | N.A. | Sterile, nonpyrogenic, preservative-free, freeze-dried powder | Intravenous Injection | Coagulants and Thrombotic agents | Coagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
1201 | Th1026 | Anistreplase | SYQVICRDEKTQMIYQQHQS Full view | 255 | Ic | Hematological,Metabolic | Eminase | Wulfing Pharma GmbH | Dry powder | Intravenous infusion | Thrombolytic Agents, Fibrinolytic agents | Plasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1 |
1205 | Th1027 | Insulin Regular | A-chain:GIVEQCCTSIC< Full view | 51 | Ia | Genetic/Hormonal | Humulin R | Eli Lilly and Company | Sterile, clear, aqueous, and colorless solution | Subcutaneous injection in the abdominal wall, the thigh, the gluteal region or in the upper arm and Intravenousadministration of Humulin R (insulin (human recombinant)) U-100 is possible under medical supervision. | Antidiabetic Agents | Insulin receptor,Insulin-like growth factor 1 receptor,Retinoblastoma-associated protein,Cathepsin D,Insulin-degrading enzyme,Neuroendocrine convertase 2,Carboxypeptidase E,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-r |
1206 | Th1027 | Insulin Regular | A-chain:GIVEQCCTSIC< Full view | 51 | Ia | Genetic/Hormonal | Novolin R | Novo Nordisk | Sterile, clear, aqueous, and colorless solution | Subcutaneous and Intravenous infusion | Antidiabetic Agents | Insulin receptor,Insulin-like growth factor 1 receptor,Retinoblastoma-associated protein,Cathepsin D,Insulin-degrading enzyme,Neuroendocrine convertase 2,Carboxypeptidase E,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-r |
1210 | Th1028 | Tenecteplase | SYQVICRDEKTQMIYQQHQS Full view | 255 | Ib | Hematological,Metabolic | TNKase | Genentech Inc | Sterile, white to off-white, lyophilized powder | Intravenous Injection | Thrombolytic Agents, Fibrinolytic agents | Plasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1,Plasminogen activator inhibitor 2,Tetranectin,Keratin, type II cytoskeletal 8,Annexin A2,Calreticulin,Calnexin,Prolow-density lipoprotein |
1234 | Th1032 | Coagulation factor VIIa | ANAFLEELRPGSLERECKEE Full view | 255 | Ib | Hematological,Metabolic | NovoSeven | Novo Nordisk | Sterile, white lyophilized powder | Injection | Thrombotic Agents, Coagulants | Coagulation factor X,Serine protease hepsin,Tissue factor pathway inhibitor,Vitamin K-dependent gamma-carboxylase,Coagulation factor VII,Tissue factor |
1246 | Th1034 | Palifermin | SYDYMEGGDIRVRRLFCRTQ Full view | 140 | Ib | Cancer | Kepivance | Amgen Inc | Sterile, lyophilized powder | Intravenous infusion | Anti-Mucositis Agents | Fibroblast growth factor receptor 2,Neuropilin-1,Fibroblast growth factor receptor 1,Fibroblast growth factor receptor 4,Fibroblast growth factor receptor 3,Basement membrane-specific heparan sulfate proteoglycan core protein |
1331 | Th1047 | Alpha-1-proteinase inhibitor | EDPQGDAAQKTDTSHHDQDH Full view | 255 | IIa | Metabolic/Geneti/Respiratory | Aralast | Baxter | Lyophilized powder | Intravenous infusion | Serine Proteinase Inhibitors, Enzyme replacement agents, trypsin inhibitors | Neutrophil elastase |
1332 | Th1047 | Alpha-1-proteinase inhibitor | EDPQGDAAQKTDTSHHDQDH Full view | 255 | IIa | Metabolic/Geneti/Respiratory | Prolastin | Talecris Biotherapeutics C formerly Bayer | Lyophilized powder | Intravenous infusion | Serine Proteinase Inhibitors, Enzyme replacement agents, trypsin inhibitors | Neutrophil elastase |
1385 | Th1061 | Trastuzumab | Light chain 1: DIQMT Full view | 1364 | IIa | Cancer | Herceptin | Genentech | Sterile, white to pale yellow, preservative-free lyophilized powder |  Intravenous administration | Antineoplastic Agents | Insulin receptor,Insulin-like growth factor 1 receptor,Insulin-degrading enzyme,HLA class II histocompatibility antigen, DQ alpha 2 chain,HLA class II histocompatibility antigen, DQ beta 1 chain,Retinoblastoma-associated protein,Cathepsin D,Carboxypeptidase E,Neuroendocrine convertase 2,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-related protein 2,Insulin-like growth factor-binding protein 7,Synaptotagmin-like protein 4 |
1389 | Th1062 | Rituximab | Heavy Chain: QVQLQQP Full view | 664 | IIa | Cancer/Immunological | Rituxan | Biogen Idec Inc., and Genentech USA, Inc | Sterile, clear, colorless, preservative-free liquid concentrate |  Intravenous administration | Antineoplastic Agents, Immunologic Factors and Antirheumatic Agents | B-lymphocyte antigen CD20,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c, Receptor tyrosine-protein kinase erbB-2,Epidermal growth factor receptor,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor I |
1434 | Th1074 | Alglucerase | ARPCIPKSFGYSSVVCVCNA Full view | 497 | Ia | Metabolic | Ceredase | Genzyme Corporation | Clear sterile non-pyrogenic solution of alglucerase in a citrate buffered solution | Intravenous injection | Enzyme Replacement Agents | Plasminogen,Proteinase-activated receptor 1 |
1439 | Th1077 | Urofollitropin | Alpha chain:APDVQDCP Full view | 203 | Ib | Hormonal | BRAVELLE | Ferring Pharmaceuticals Inc. | Sterile, lyophilized powder used after reconstitution with sterile 0.9% Sodium Chloride Injection | Intramuscular and Subcutaneous administration | Fertility Agents | Glutamate carboxypeptidase 2 |
1440 | Th1077 | Urofollitropin | Alpha chain:APDVQDCP Full view | 203 | Ib | Hormonal | Metrodin | N.A. | Sterile, lypholized form contains an acidic, water soluble glycoprotein biologically standardized for FSH gonadotropin activity | Intramuscular injection. | Fertility Agents | Glutamate carboxypeptidase 2 |
1441 | Th1077 | Urofollitropin | Alpha chain:APDVQDCP Full view | 203 | Ib | Hormonal | Fertinex | N.A. | Sterile, lyophilized form contains an acidic, water soluble glycoprotein biologically standardized for FSH gonadotropin activity | Subcutaneous injection. | Fertility Agents | Glutamate carboxypeptidase 2 |
1456 | Th1086 | Interferon Alfa-2B, Recombinant | CDLPQTHSLGSRRTLMLLAQ Full view | 165 | Ib | Immunological | INTRON® A | Merck | Powder or solution | Intramuscular, Subcutaneous, Intralesional, or Intravenous injection | Immunosuppressive Agents | Granulocyte colony-stimulating factor receptor,Neutrophil elastase, Coagulation factor X,Coagulation factor XI,Coagulation factor VII,Coagulation factor VIII,Prothrombin,Prolow-density lipoprotein receptor-related protein 1,Vitamin K-dependent gamma-carboxylase, Platelet-derived growth factor receptor beta,Platelet-derived growth factor receptor alpha,Alpha-2-macroglobulin |
1560 | Th1121 | Pertuzumab | light chain DIQMTQSP Full view | 664 | IIIc | Cancer | Perjeta | Genentech | Sterile, clear to slightly opalescent, colorless to pale brown liquid | Intravenous infusion | Monoclonal antibodies | Receptor tyrosine-protein kinase erbB-2 |
1602 | Th1128 | Velaglucerase Alfa | ARPCIPKSFGYSSVVCVCNA Full view | 497 | Ia | Hormonal | VPRIV | Shire | Sterile, preservative free, lyophilized powder | Intravenous infusion | Enzymes | Glucosylceramidase |
1659 | Th1152 | Drotrecogin alfa | Heavy Chain: LIDGKMT Full view | 402 | Ib | Infectious | Xigris | Eli Lilly and Company | Sterile, lyophilized, white to off-white powder | Intravenous Infusion | Antisepsis | Coagulation factor VIII, V, Plasminogen activator inhibitor 1, Thrombomodulin, Vitamin K-dependent protein S, Ceruloplasmin, Prothrombin, Platelet factor 4, Plasma serine protease inhibitor, Serpin B6, Vitamin K-dependent gamma-carboxylase, Endothelial protein C receptor |
1663 | Th1155 | Urokinase | KPSSPPEELKFQCGQKTLRP Full view | 276 | Ib | Haemetological | Kinlytic | N.A. | Sterile lyophilized white powder | Intravenous infusion | N.A. | Plasminogen,Urokinase plasminogen activator surface receptor, Urokinase-type plasminogen activator, Tissue-type plasminogen activator, Plasminogen activator inhibitor 1, 2, Plasma serine protease inhibitor, Low-density lipoprotein receptor-related protein 2, Suppressor of tumorigenicity 14 protein, Nidogen-1 |
1678 | Th1162 | Alirocumab | NA Full view | 0 | Ic | Metabolic/Cardiac | Praluent | Sanofi Aventis U.S. Llc | Injection, Solution | Subcutaneous | N.A. | Proprotein convertase subtilisin/kexin type 9 |
1679 | Th1162 | Alirocumab | NA Full view | 0 | Ic | Metabolic/Cardiac | Praluent | Sanofi Aventis Canada Inc | Solution | Subcutaneous | N.A. | Proprotein convertase subtilisin/kexin type 10 |
1680 | Th1162 | Alirocumab | NA Full view | 0 | Ic | Metabolic/Cardiac | Praluent | Sanofi Aventis Canada Inc | Solution | Subcutaneous | N.A. | Proprotein convertase subtilisin/kexin type 11 |
1681 | Th1162 | Alirocumab | NA Full view | 0 | Ic | Metabolic/Cardiac | Praluent | Sanofi Aventis U.S. Llc | Injection, Solution | Subcutaneous | N.A. | Proprotein convertase subtilisin/kexin type 14 |
1715 | Th1171 | C1 Esterase Inhibitor (Human) | NA Full view | 0 | Ia | Genetic Disorders | Berinert 1500 | Csl Behring Canada Inc | kit; Powder for Solution | Intravenous | NA | Plasma protease C1 inhibitor |
1717 | Th1171 | C1 Esterase Inhibitor (Human) | NA Full view | 0 | Ia | Genetic Disorders | Cinryze | Viropharma Biologics Inc | Powder for Solution | Intravenous | NA | Plasma protease C1 inhibitor |
1724 | Th1174 | Daratumumab | NA Full view | 0 | IIIc | Cancer | Darzalex | Janssen Biotech, Inc. | Solution, concentrate | Intravenous | Antineoplastic Agents | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 |
1736 | Th1177 | Elosulfase alfa | APQPPNILLLLMDDMGWGDL Full view | 496 | Ia | Metabolic Disorders | Vimizim | Biomarin International Limited | Solution | Intravenous | Enzymes; Alimentary Tract and Metabolism | N-acetylgalactosamine-6-sulfatase |
1741 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | NA | NA | Injection, Solution; Injection | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 9 |
1742 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | Repatha | Amgen Inc | Injection, Solution | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 10 |
1743 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | Repatha | Amgen Canada Inc | Solution | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 11 |
1744 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | Repatha | Amgen Inc | Injection, Solution | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 12 |
1821 | Th1212 | Insulin Pork | A chain GIVEQCCTSICS Full view | 68 | Ia | Metabolic Disorders | Iletin II | Lilly | sterile suspension | Subcutaneous | Hypoglycemic Agents, Antidiabetic Agents | Insulin receptor, Insulin-like growth factor 1 receptor, Insulin-degrading enzyme, HLA class II histocompatibility antigen, DQ alpha 2 chain, HLA class II histocompatibility antigen, DQ beta 1 chain, Retinoblastoma-associated protein, Cathepsin D, Carboxypeptidase E, Neuroendocrine convertase 2, Neuroendocrine convertase 1, Protein NOV homolog, Low-density lipoprotein receptor-related protein 2, Insulin-like growth factor-binding protein 7, Synaptotagmin-like protein 4, Cytochrome P450 1A2 |
1848 | Th1236 | Sipuleucel-T | NA Full view | 0 | IIIc | Cancer | Provenge | NA | Solution | Intravenous | Antineoplastic and Immunomodulating Agents | Prostatic acid phosphatase |